A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, ...

A drug combination already used in advanced prostate cancer now appears to significantly extend survival when given earlier.

In a meeting Tuesday, the Prostate Cancer Study Committee heard the final recommendations on how to fight prostate cancer in ...

Combining 177 Lu-PSMA-617 with SOC produced statistically significant rPFS, reducing the risk of radiographic progression or death by 28% (HR 0.72; 95% CI, 0.58-0.90) vs SOC alone in patients with ...

Prostate cancer is the most common cancer among men after skin cancer, with approximately 1 in 8 men diagnosed in their ...

Prostate cancer is the most common form of cancer in the UK, according to Prostate Cancer UK. Cancer Research UK says ...

One in every 8 men in the United States will develop prostate cancer, according to prostate cancer statistics released by the American Cancer Society.

Researchers found that late-stage, or distant-stage, prostate cancer is increasing across all age groups, including by approximately 3% annually in men under 55 and by 6% in those 55 and older. The ...

Targeting prostate-specific membrane antigen, Lu-PSMA-617 has demonstrated clinical benefits in patients with PSMA-positive ...

There is widespread misinformation when it comes to prostate cancer. Oncologist Dr Sudipto De debunks 4 myths and stresses the importance of regular screenings.

“As part of a treatment plan for prostate cancer, President Biden is currently undergoing radiation therapy and hormone ...

Outside prostate cancer, Truqap is FDA-approved with fulvestrant (Faslodex) for patients with hormone receptor-positive, HER2 ...